Q-omics provides the consensus-scored MIR744 profile across patient tissues and cancer cell-line models. MIR744 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MIR744 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, MIR744 RNA expression shows 9,392 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, KIRC, and TGCT as cancer lineages where MIR744 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR744 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR744 survival associations across molecular data types. MIR744 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR744 RNA expression–survival associations across cancer types. High MIR744 expression shows unfavorable associations in UVM, but favorable associations in BRCA, PAAD, LUAD, LAML and THCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for MIR744 RNA expression.
This table summarizes MIR744 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR744. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR744 shows lower tumor expression in KIRC, THCA, LUSC, LUAD and KICH and higher tumor expression in LUAD. The KIRC box plot shows higher MIR744 RNA expression in normal versus tumor tissue (log2 FC = −0.472, t-test p < 0.001).
This table shows molecular features associated with MIR744 in patient tissues and cancer cell lines. In patient samples, MIR744 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
